Alcobra's MDX Meets Primary Endpoint in Phase II Safety and

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Alcobra's MDX Meets Primary Endpoint in Phase II Safety and Tolerability Clinical Trial in Adolescents With ADHD

TEL AVIV, Israel, March 10, 2015 (GLOBE NEWSWIRE) -- Alcobra Ltd. (Nasdaq: ADHD ), an emerging pharmaceutical company focused on the development of new medications to help patients with cognitive disorders, including Attention Deficit Hyperactivity Disorder (ADHD) and Fragile X Syndrome, today announced that its Phase II safety and tolerability study of a single administration of MDX in adolescent patients with ADHD achieved its primary endpoint. In the study, MDX showed good tolerability and no safety concerns were identified. The profile of adverse events in the MDX treated group was not different from the placebo comparator group. There were no reported cases of discontinuation from the study due to adverse events.

A total of 83 patients enrolled in the Phase II trial, which was a multi-center, randomized, double-blind, placebo controlled, fixed dose study designed to evaluate the safety and tolerability of a single administration of MDX in adolescents (aged 13-17) with predominantly inattentive ADHD. Following a screening period, patients were exposed to either placebo or one of three MDX dose options determined by their weight and followed for several hours that day. Patients returned several days after this treatment visit for a safety follow-up visit.

Patients' baseline characteristics were similar between MDX and placebo groups. The most common side effects were headache (8% of patients in the MDX group and 12% in the placebo group), nausea (3% vs. 5%) and fatigue (3% vs. 5%). No clinically significant safety findings in laboratory values, vital sign measurements, ECG parameters, cardiovascular parameters or findings during clinical examination were observed. Analyses of secondary cognitive measures, after a single administration of MDX compared to placebo, did not produce statistically significant findings, yet resulted in an efficacy signal on the Test of Variables of Attention (TOVA) assessments Response Time and Errors of Omission.

"The successful completion of this safety study is an important milestone in the development of MDX and supports our ability to advance into efficacy trials of MDX for pediatric ADHD," said Dr. Yaron Daniely, President and Chief Executive Officer of Alcobra. "I would like to thank all the patients who participated in the trial and their parents, as well as our investigators who quickly and rigorously conducted this trial over the last few months."

The study is the first clinical trial using MDX in a pediatric ADHD population. For further information on this clinical trial, please visit https://ClinicalTrials.gov/ , Identifier: NCT02189772. A separate study evaluating MDX in adolescents and adults with Fragile X Syndrome is currently underway and actively enrolling patients. Results of the Fragile X Study are expected to be reported by the end of 2Q15.

About MDX

MDX (Metadoxine Extended Release (MG01CI)) is a proprietary investigational new drug candidate being developed by Alcobra for the potential treatment of ADHD and Fragile X Syndrome. MDX is not a stimulant and acts as a monoamine-independent modulator of GABA (gamma-aminobutyric acid) transmission. This novel mechanism of action does not directly affect dopamine or norepinephrine. In studies to date, metadoxine has shown no potential for abuse or addiction. MDX is currently in Phase III development for adults with ADHD and Phase II development for pediatric ADHD. A study of MDX is also ongoing in adolescents and adults with Fragile X Syndrome.

About Attention Deficit Hyperactivity Disorder (ADHD)

ADHD is a common and impairing neuropsychiatric condition. Once believed to only affect children, ADHD is now known to persist into adolescence and adulthood in a sizeable number of cases. Key symptoms of ADHD include inattention, hyperactivity and impulsivity.

According to the Centers for Disease Control and Prevention, about 9% of children in the U.S. meet criteria for ADHD with similar numbers reported in other countries. Although boys are more commonly diagnosed, ADHD is also common in girls who often go undiagnosed. Approximately 4-5% of adults worldwide are affected with ADHD, yet most adults with ADHD remain undiagnosed and untreated. There is no known cause of ADHD, however studies suggest that genetics may play a role.

About Alcobra Ltd.

Alcobra Ltd. is an emerging pharmaceutical company primarily focused on the development and commercialization of a proprietary drug candidate, MDX, to treat cognitive disorders including ADHD and Fragile X Syndrome. MDX has completed multiple Phase II studies in adults and adolescents with ADHD and has completed a Phase III study in adults with ADHD. The company is conducting a Phase II trial in adolescents and adults with Fragile X Syndrome. The company was founded in 2008 and is headquartered in Tel Aviv, Israel. For more information please visit the Company's website, www.alcobra-pharma.com , the content of which is not incorporated herein by reference.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. Because such statements deal with future events and are based on Alcobra's current expectations, they are subject to various risks and uncertainties and actual results, performance or achievements of Alcobra could differ materially from those described in or implied by the statements in this press release. For example, forward-looking statements include statements regarding advancement to initiate a Phase III study in pediatric ADHD, expected announcement of results of clinical trials. In addition, historic results of scientific research do not guarantee that the conclusions of future research would not suggest different conclusions or that historic results referred to in this press release would not be interpreted differently in light of additional research or otherwise. The forward-looking statements contained or implied in this press release are subject to other risks and uncertainties, including those discussed under the heading "Risk Factors" in Alcobra Ltd.'s Annual Report on Form 20-F for the fiscal year ended December 31, 2014 filed with the Securities and Exchange Commission (SEC) and in subsequent filings with the SEC. Except as otherwise required by law, Alcobra disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date hereof, whether as a result of new information, future events or circumstances or otherwise.

U.S. Investor Contacts LifeSci Advisors, LLC Michael Rice 646-597-6979 Media Inquiries Sam Brown, Inc. Mike Beyer 773-463-4211 Israel Investor Contact: Alcobra Investor Relations Debbie Kaye +972-72 2204661

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Nauticus Robotics Dive into Defense & UAE Moves

Updated Category News Views 211

Charting New Waters: Defense and UAE Focus Looking at Nauticus Robotics lately, it feels like they're finally getting the hang of balancing their defense play and UAE expansions. This quarter they're coming out swinging, dropping some fine numbers mixed with a slew of strategic moves that got me thinking twice about their place in the subsea robotics world. Financial...

Continue Reading
NeuroPace Faces Investigation After Revenue Forecast Cut

Updated Category News Views 35

NeuroPace Revenue Drama: A Blow to Investor Confidence How the mighty have stumbled—or so it feels to the folks who put their bucks into NeuroPace, Inc. (NASDAQ: NPCE). It's tough to swallow: they cut their 2026 revenue forecast from a hopeful $99.5-$101.5 million to a sobering $91-$92 million. Just one quarter apart those projections are, like a cruel twist of fate...

Continue Reading
Choate's Expands to New Mid-South Markets

Updated Category News Views 155

Family Traditions Drive Choate's Growth Back in the day, you might've thought the family-run businesses were a dying breed, right? Not in the case of Choate's Air Conditioning, Heating, Plumbing & Electrical. These folks aren't just holding the fort; they're storming new territories across the Mid-South like they've got something to prove—or maybe just something to...

Continue Reading
AppLovin Faces Legal Heat: Investors on Edge Today

Updated Category News Views 104

AppLovin's Day of Reckoning: Investors Take Note Ever find yourself caught in a whirlwind of corporate promises that slide into disappointment? Well, buckle up, because that's exactly where AppLovin finds itself today. They've stirred up a storm with investors over some questionable hyperbole about their artificial intelligence tools and ad services. Missteps and Market...

Continue Reading
equipifi's BNPL Shop: New Ammo for Credit Unions

Updated Category News Views 189

equipifi's 'Shop': The Big Play in Banking Look, here’s the deal—equipifi just lobbed a new grenade into the finance battlefield, arming credit unions and community banks with 'Shop', their own Buy Now, Pay Later (BNPL) platform. The goal? To put them toe-to-toe with the big fintech wolves—something these smaller guys desperately needed. It's a meaty move, no...

Continue Reading
Tigo Energy Faces Lawsuit: Key Details for Investors

Updated Category News Views 123

Tigo Energy Inc.'s Troubles: A Stock Drop and Legal Woes You see, not every day do you wake up to find your investment taking a nose dive by 36.76%. But that’s exactly what happened to Tigo Energy, Inc. (NASDAQ: TYGO) after some shaky announcements. A Rollercoaster for Investors On August 4, 2026, Tigo hit investors with a one-two punch: revised financial outlook and...

Continue Reading
Texxon Faces Revenue Slide Amid Strategic Shifts

Updated Category News Views 68

Texxon's Strategic Transitions and Financial Headaches Texxon Holding Limited (NASDAQ:NPT) just laid their cards on the table, unveiling a mixed bag in their fiscal year 2026 results. As the world's chemical and plastics scene faces winds of change, Texxon buckled down and tried to steer the ship clear from the rocks. It's a balancing act juggling market headwinds, a new...

Continue Reading
Operation Healing Forces Partners with Wounded Warrior

Updated Category News Views 56

Joining Forces for Special Operations Families When it comes to the heavy lifting of supporting Special Operations Forces (SOF) families, two powerhouses—Operation Healing Forces (OHF) and Wounded Warrior Project (WWP)—are doubling down. They’re not just tossing around good intentions. Oh no, they’re pulling out the stops with a solid partnership focused on...

Continue Reading
Duolingo Faces Class Action: Key Investor Steps

Updated Category News Views 126

Navigating Turbulent Times with Duolingo Holy moly, the dumpster fire that is the Duolingo (NASDAQ:DUOL) legal saga just got hotter. If you snagged yourself some shares between May 2, 2025, and February 26, 2026, you'd better sit down and grab some antacids—because the nauseating roller coaster is far from over. Robbins LLP is rounding up the troops for a class action,...

Continue Reading
SiteOne Joins S&P SmallCap 600 Amid KKR's Integer Buyout

Updated Category News Views 142

Changes on the SmallCap Horizon Starting off, SiteOne Landscape Supply (NYSE: SITE) is hopping onto the S&P SmallCap 600 bandwagon. This shift activates just as the market revs up on November 19, 2026. SiteOne is stepping in as Integer Holdings Corp. (NYSE: ITGR) makes its grand exit, a move prompted by a significant acquisition by KKR & Co. Inc. (NYSE: KKR). KKR’s...

Continue Reading

Top 5 Most Recently Viewed Articles

Nauticus Robotics Reports Exciting Q3 2025 Financial Results

Updated Category News Views 251

Nauticus Robotics Shows Strong Performance in Q3 2025 Nauticus Robotics, Inc. (NASDAQ: KITT), an industry leader in subsea robotics, has recently made headlines with their impressive financial performance during the third quarter of 2025. This period marked a remarkable increase in customer interest, innovative capabilities, and upcoming product launches that promise to...

Continue Reading
Nano Labs' Strategic Move to Nasdaq Global Market: Key Benefits

Updated Category News Views 152

Nano Labs Elevates to Nasdaq Global Market Nano Labs Ltd (Nasdaq: NA), a frontrunner in Web 3.0 infrastructure and product solutions, has officially announced its uplisting to the Nasdaq Global Market. This significant move is designed to provide enhanced opportunities for growth and stability, marking an exciting chapter for the company and its shareholders. Impact of...

Continue Reading
The EVERY Company Strengthens Its Patent Portfolio in Europe

Updated Category News Views 169

The EVERY Company Enhances Its Intellectual Property The EVERY Company, a prominent innovator in protein ingredients, has recently secured a significant patent for its recombinant ovalbumin in the European Union. This development consolidates its position as a leader in crafting functional protein ingredients, paving the way for its growth and expansion within the global...

Continue Reading
Discover the Compounding Success of Analog Devices Over a Decade

Updated Category News Views 204

How $100 Invested in Analog Devices Transformed Over 10 Years Analog Devices (NASDAQ: ADI) has had a remarkable journey over the past decade, outperforming the market with an annualized growth of 2.67%, resulting in an impressive average annual return of 14.15%. As of the latest figures, Analog Devices boasts a market capitalization of approximately $118.16 billion. The...

Continue Reading
Mustang Bio Secures $8 Million in Public Offering Success

Updated Category News Views 118

Mustang Bio Completes $8 Million Public Offering Mustang Bio, Inc. (Nasdaq: MBIO), a prominent company in the biopharmaceutical sector, renowned for its innovative cell therapies, recently announced the successful closure of a public offering that raised approximately $8 million. This financial milestone signifies a major step forward for the company as it aims to drive...

Continue Reading